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The complex network of specialized cells and mole-
cules in the immune system has evolved to defend
against pathogens, but inadvertent immune system
attacks on ‘‘self’’ result in autoimmune disease. Both
genetic regulation of immune cell levels and their rela-
tionshipswithautoimmunityare largelyundetermined.
Here, we report genetic contributions to quantitative
levels of 95 cell types encompassing 272 immune
traits, in a cohort of 1,629 individuals from four clus-
teredSardinian villages.Wefirst estimated trait herita-
bility, showing that it can be substantial, accounting
for up to 87% of the variance (mean 41%). Next, by
assessing 8.2 million variants that we identified and
confirmed in an extended set of 2,870 individuals, 23
independent variantsat13 loci associatedwithat least
one trait. Notably, variants at three loci (HLA, IL2RA,
and SH2B3/ATXN2) overlap with known autoimmune
disease associations. These results connect specific
cellular phenotypes to specific genetic variants, help-
ing to explicate their involvement in disease.
INTRODUCTION
The immune system must defend against a huge variety of
microbes and remember them. To accomplish this and kill242 Cell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc.cancer-transformed and virus-infected cells while recognizing
and tolerating our own untransformed components requires
the formation and regulation of a wide range of both generalist
and specialist white cell (leukocyte) types. A fluorescence-
activated cell sorting (FACS) approach has facilitated highly
sensitive, simultaneous analysis of levels of these leukocyte
subpopulations and is being used by the Human Immunology
Project to characterize the immunological profile of healthy and
sick individuals (Davis, 2008; Maecker et al., 2012).
Despite methodological advances, searches for connections
between genetic variants and cellular immune phenotypes
have typically proceeded by examining broad classes of immune
cells (Ferreira et al., 2010; Nalls et al., 2011; Okada et al., 2011),
and even the extent to which variation in immune cell subtypes
is heritable is still unknown.
Here, we use FACS to profile extensively the human immune
cell repertoire for a large population sample. Applying state-of-
the-art genotyping and sequencing technologies to the same
individuals, we proceed to dissect the inherited phenotypic
structure of the human immune cell repertoire. Importantly,
our results demonstrate connections between known immune-
related disease risk alleles and levels of particular immune
cell types, thus representing an important extension of pre-
vious autoimmune disease GWAS. Our hypothesis-generating
approach, using individuals from a general population, is also
distinct from hypothesis-driven comparisons of immune cell
types between cases and controls, which can be hampered by
limited a priori knowledge and affected by second-order effects
due to the disease process or its therapy.
Figure 1. Studied Leukocyte Subpopulations
Color-coded diagram of the cell types analyzed by flow cytometry with arrows depicting the hierarchical levels of separation of circulating cell populations
(leukocytes) and constituent subsets of the two main arms, innate and adaptive, of the immune system. Innate cell types, which provide prompt but generic
responses to aggressors, include granulocytes (yellow), monocytes (pale blue), and dendritic cells (red). Adaptive cell types, which provide highly specific
responses to microbial targets and may maintain a ‘‘memory’’ that enables a faster and greater response to previously encountered pathogens, include B cells
(magenta) and T cells (green). The natural killer cells (orange) share features of both arms of the immune system. The name and, when relevant, the identifying
marker are indicated beside each population. Cells inside a light-blue rectangle were phenotypically characterized with the antigen pointed to by the adjacent
light-blue arrow; for example, the six CD3+ subsets (CD4 CD8, CD4+, CD4+ CD8 dim, CD4+ CD8br, CD8br, and CD8 dim) are shown within a blue rectangle
and were further subdivided into naive, central memory, effector memory, and terminally differentiated cells. The red rectangle indicates that the included
cell populations have been jointly analyzed for CD39, the marker indicated by the red arrow. For simplicity, 45 of the 95 analyzed cell types, described in the full
text, are shown. See also Figure S1 and Table S1.RESULTS AND DISCUSSION
Profiling the Human Immune Cell Repertoire
By FACS analyses, we characterized a wide range of circulating
cell subtypes in an initial sample of 1,629 individuals enrolled
in the SardiNIA study population cohort. The cells comprise
the major leukocyte populations in peripheral blood (Figure 1),
including monocytes, granulocytes, circulating dendritic cells
(cDCs), natural killer (NK), B cells, and T cells, with a more
detailed characterization of T cell subsets. More specifically,
because of their functional relevance and potential involvement
in many autoimmune and inflammatory diseases, we focused
on T cells subdivided according to their maturation and acti-vation status, including subsets of regulatory T cells (Tregs)
(Shevach, 2000; Wing and Sakaguchi, 2010). Overall, we defined
a total of 95 cell types that were further assessed with respect
to their parental and grandparental cell lineages, resulting in
272 evaluated immunophenotypic traits (Experimental Proce-
dures and Figure 1; Figure S1 and Tables S1A–S1C available
online).
Heritability and Correlations between Traits
We estimated heritability of circulating immune cell counts in the
first 1,629 phenotyped individuals (Experimental Procedures),
observing values from 3% to 87% (mean 41%). The most herita-
ble traits corresponded to Tregs and their subsets (mean 55%)Cell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc. 243
Figure 2. Phenotypic and Genetic Clustering
Heatmap of phenotypic (lower-right triangle) and genetic (upper-left triangle) correlations for cell counts and CD4:CD8 and T:B cell ratios. Traits with a phenotypic
correlationR0.99 were excluded (Extended Experimental Procedures). Genetic and phenotypic triangles follow the same trait order, dictated by the clustering of
phenotypic correlations, and the dendrogram at the right reflects the clustering. Traits connected by short branches share stronger phenotypic correlation,
whereas traits that join near the root of the tree are weakly correlated. Color gradations indicate correlation strength, with red indicating direct correlation
(from 0 to +1) and blue inverse correlation (from 0 to 1). See also Figure S2 and Table S2 for further details.(Figure S2; Table S2A provides descriptive statistics and impact
of age and gender covariates). Remarkably, most cell popu-
lations with very high heritability (>60%) were positive for the
CD39 marker (see below). Gender typically had negligible
effects on phenotypic variation; age was important for a subset
of cellular phenotypes, especially the previously characterized
reduction in naive CD8 T cells that might explain reduced vacci-
nation success in the elderly (Buchholz et al., 2011; Sansoni
et al., 2008).
By their nature, many traits are hierarchically and functionally
correlated, as the different immune cell types originate from a
limited number of common progenitors and interact continu-244 Cell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc.ously. To examine these relationships, we performed a bivariate
analysis to estimate phenotypic and genetic correlation coeffi-
cients, i.e., the proportion of variance between each pair of traits
due to the combined contribution of genetic and environmental
factors and the variance attributable to genetic causes only,
respectively (Extended Experimental Procedures). A depiction
of the genetic and phenotypic correlations between cell counts
and CD4:CD8 and T:B cell ratios is presented in the heat
map (Figure 2). Similarities but also important differences in the
patterns of genetic and phenotype correlation coefficients—
reported in the upper and lower triangles of the figure delimited
by the central diagonal—are immediately apparent. On the one
Figure 3. Manhattan Plot of Best p Values
For each SNP, the best p value observed among all assessed traits is plotted on a –log10 scale (y axis), according to its genomic coordinates (x axis). SNPs are
colored in blue if the corresponding best p value was directly genotyped with ImmunoChip (IC) or Cardio-MetaboChip (MC) and in gray if imputed from genomic
sequencing of Sardinians. The dotted horizontal line indicates the threshold for declaring a locus genomewide to be significant (5.263 1010). The best candidate
gene is indicated near the peak. Loci below the significance threshold and previously described are marked with an asterisk.hand, two large squares in the upper part of the diagonal
are indicative of conjoint genetic and phenotypic correlations
and tend to involve cells with markers, such as CD39 and
CD45RA, whose expression is under strong genetic control
(see next section), suggesting that the extent of similarity
between traits reflects intrinsic relations dictated mainly by
ontogenesis and coordinated evolution of traits—and hence
shared antigen expression. On the other hand, the overall
phenotypic correlations tend to be stronger than genetic correla-
tions, consistent with additional effects of nongenetic factors on
cell levels. An example of strong positive phenotypic but not
corresponding strong genetic correlation is observed between
some DC and Treg subsets (corresponding to the lower-right
red cluster), in line with a mechanism by which an increase of
DCs is controlled by an increase of Tregs (Wing and Sakaguchi,
2010).Genetic Changes Affecting Immune Cell Traits
To identify the genetic variation accounting for the inherited
component of the 272 immunophenotypic traits, we next
performed a sequencing-based GWAS, assessing 8.2 million
variants in the 1,629 phenotyped individuals (Experimental
Procedures). At the significance threshold of p < 5.26 3 1010,
we identified 21 signals at 11 loci, linking genetic variation to
multiple cellular immunophenotypes and resulting in a total of
180 SNP-trait associations. We also replicated (p < 5 3 108)
two previously suggested associations (Ferreira et al., 2010), re-
sulting in a total of 23 association signals at 13 loci, which were
thenassessedandunequivocally confirmed in theextendedsam-
ple set of 2,870 individuals, including 1,241 additional volunteers
(Figures 3 and 4, Data S1, and Tables 1, S4A, S4B, and S5A).
The amount of phenotypic variation explained was always
>2%, consistent with the expected statistical power of ourCell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc. 245
Figure 4. Regional Plot and Box Plot for the Top Signal in ENTPD1
(A and B) Representation of the association in the genomic context (A) and in the biological context (B) for the most strongly associated variant at the ENTPD1
gene.
(A) Representation of the association strength (y axis shows the –log10 p value) versus the genomic positions (on hg19/GRCh37 genomic build) around the most
significant SNP, which is indicated with a purple circle. Other SNPs in the region are color coded to reflect their LD with the top SNP, as in the left inset (taken from
pairwise r2 values calculated on Sardinian haplotypes), whereas symbols reflecting genomic functional annotation are indicated in the right inset. Genes and the
position of exons, as well as the direction of transcription, are noted in lower boxes. This plot was drawn using the standalone version of the LocusZoom package
(Pruim et al., 2010).
(B) The distribution of the immunophenotypic levels within each genotype class considering the normalized trait adjusted for age and gender in relation to the
1,629 initial samples, showing the additive effect that was statistically observed.
See also Data S1.sample, with nine variants explaining >5% and three variants
>15% (Table 1). Considering the 132 traits for which we ob-
served at least one genome-wide significant signal, the heritabil-
ity explained ranged from 3.7% to 90.3%, and the proportion of
explained heritability was >50% for 35 traits and >80% for four
traits (Figure 5 and Table S2A), showing relatively large effects
for human quantitative traits (Teslovich et al., 2010; Lango Allen
et al., 2010).
Among the largest genetic effects detected, a single intronic
variant of ENTPD1, coding for CD39, accounted for 60.8% of
phenotypic variation (and 72% of the heritability) of the levels
of CD39+activated CD4+ Tregs (Table 1 and Figure 4). Thus,
this association has an obvious candidate mechanism in which
cis-acting variation regulates the expression of a key marker in
individual cells and therefore determines the number of cells
expressing this molecule. CD39 is an ectoenzyme, expressed
on monocytes, neutrophils, B, T, and NK cells (Pulte et al.,
2007), which hydrolyzes extracellular ATP and ADP to AMP.
Notably, among T cells, CD39 is mainly expressed by activated
CD4+ Tregs, where it has an anti-inflammatory function by
reducing extracellular proinflammatory ATP (Borsellino et al.,
2007).
Other clear biological candidates among our lead associations
included a variant near IL2RA, a gene encoding the transmem-
brane protein CD25 and associated with variation of T cells ex-
pressing high CD25 levels (CD45RA CD25hi CD4+ not Treg246 Cell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc.cells); a variant near the CD8A and CD8B genes, encoding the
cell surface glycoprotein CD8 and associated with variation in
the level of T cells expressing CD8 (CD4+ CD8 dim); a variant
near the HLA class II transactivator (CIITA) gene associated
with the levels of activated T cells (i.e., HLA DR+ T lymphocytes);
and a variant in the TNFSF13B gene associated with the levels
of B cells. Notably, CIITA encodes a transcription factor influ-
encing HLA class II expression, whereas TNFSF13B encodes
the B-cell-activating factor of the TNF family (BAFF), inactivation
of which is specifically associated with loss of mature circulating
B cells (Table 1) (Mackay and Schneider, 2009).
Overall, 19 of the 23 variants reported here were associated
with multiple traits, often with divergent effects on different traits
(Tables S4A and S5A). A further layer of complexity was added
by instances of multiple independent associations with the
same traits within a single associated region. For example, inde-
pendent variants within a region encompassing the GALM and
HNRPLL genes (Table 1) increased the percentage of naive
and terminally differentiated T cell subpopulations (those that
are CD45RA positive), with corresponding decreases in the
percentage of the memory T cell subsets (which are CD45RA
negative). Association with HNRPLL is fully concordant with its
role as the master regulator of CD45 splicing, a hallmark of
T cell maturation (Wu et al., 2010). By contrast, the biology
underlying the associations with GALM is less clear, though
variants in GALM may act in long-distance regulation of
HNRPLL because they fall in DNA regions known to interact with
its promoter (Table S6A) (Li et al., 2012).
Other examples of multiple independent signals clustered in
the same gene regions and associated with several traits
were found near ENTPD1 and in the HLA region (Table 1), where
multilocus and multiallelic associations with complex diseases
have been extensively documented (Marrosu et al., 2001). These
results illustrate a new role for HLA variants, modulating immune
system function by affecting the level of specific immune cell
types. Of note, several variants in HLA class I alleles were asso-
ciated with variation in the levels of numerous distinct CD8+
T cell subtypes, consistent with the notion that self-class I
MHC molecules support CD8+ T cell survival (Takada and
Jameson, 2009).
In general, most of the associations reported in this work
are new, though some are consistent with previously detected
signals. Specifically, we confirmed the putative associations
between NK cell levels and variants near the Schlafen gene
cluster and the association of CD4+ T cells with variation in the
SH2B3/ATXN2 gene region (Ferreira et al., 2010).
In addition to associations with p < 5.263 1010, we observed
several additional signals at p < 53 108 (Table S5B) that require
confirmation by further analyses. Most of them are likely to be
genuine—for example, the association of a common nonsynon-
ymous variant (N1639S) in the lactase gene (LCT) with pDCs.
It is striking that the association of two independent missense
variants at this locus with leukocyte count in African Americans
was recently reported (Auer et al., 2012), further supporting an
unanticipated role of coding variation within this locus in the
regulation of immune cell levels.
Our results also highlight the benefit of imputation and
sequencing-based GWAS, both in detection of association sig-
nals and in the identification of the causal genes and variants
(so-called ‘‘fine mapping’’), which is relevant for downstream
functional studies. In fact, 3 of the 13 detected loci (NCAM,
CD4, and HLA-E) reached significance only after imputation.
Across all loci, 20 lead variants were imputed, and 2 of them
were not present even in the HapMap data set or in the most
recent 1000 Genomes release and thus were not directly acces-
sible by imputation from external resources. One, rs58055840,
has proxies in the 1000 Genomes panel, but the other,
chr10:98088623, is not strongly correlated with other known
markers. Further investigation is required to determine whether
these variants are specific to Sardinians.
Functional Clues from the Associated Variants
The 23 lead variants are located in noncoding regions, although
two of themare in strong linkage disequilibrium (LD) (r2 > 0.8) with
nonsynonymous coding variants (with features of variants
detailed in Table S4C). Furthermore, seven variants fall within
known elements with regulatory capacity, including repressors,
enhancers, and promoter elements or transcription-factor-bind-
ing sites (Table S6A). To assess functional processes and path-
ways throughwhich the variants exert their effects, we selected a
set of candidate genes based on physical position and biological
features and surveyed Gene Ontology (GO) terms and pathway
enrichment (Experimental Procedures and Table 1). As ex-
pected, even when genes located in the HLA region wereexcluded, the overrepresented pathways and GO categories
were predominantly related to immune function (e.g., immune
response, immune system process, primary immunodeficiency,
hematopoietic cell lineage, antigen processing and presentation,
T cell receptor complex, IgG binding, MHC protein binding, and
IL12-mediated signaling events) (Table S6B).
Overlapping Associations between Immune Traits and
Diseases
After identifying immune-cell-associated variants, we checked
whether any of them correlated with known disease associa-
tions. After identifying immune-cell-associated variants, we sys-
tematically checked in public databases whether any of them
were, or were highly correlated (r2 > 0.8) with, a known dis-
ease-associated variant previously reported at p < 5 3 108.
We identified overlaps at three genetic loci: HLA, IL2RA, and
SH2B3/ATXN2 (Table 2, Figure S3, and Extended Experimental
Procedures). Such overlapping associations identify specific im-
mune cell types that are unbalanced in disease status and also
suggest mechanisms by which specific risk alleles might lead
to disease susceptibility, as follows.
Variation downstream of the HLA-DRA gene decreased the
levels of memory CD8+ cells not expressing the costimulatory
molecule CD28 (CD45RA CD28 CD8+ cells) and correlated
with published associated risk alleles for ulcerative colitis, sys-
temic sclerosis, Parkinson’s disease, and Hodgkin’s lymphoma
(Barrett et al., 2009; Enciso-Mora et al., 2010; Gorlova et al.,
2011; Hamza et al., 2010).
A variant in the IL2RA gene region, rs61839660, was associ-
ated with a memory T cell subset expressing high CD25 levels
(CD45RACD25hi CD4+ not Treg cells) and is also the strongest
type 1 diabetes (T1D)-associated variant in the region (Huang
et al., 2012; Lowe et al., 2007). Moreover, association with the
same immune cells was previously observed at a variant in mod-
erate LD (r2 = 0.77), which was, at the time, the strongest T1D-
associated variant (Dendrou et al., 2009). The allele that is
responsible for an increase in the CD45RA CD25hi CD4+ not
Treg cells reduces the risk for T1D, thus linking this specific
cell type to protection against T1D. The results also suggest
that anti-CD25 therapies might increase risk for T1D by reducing
the number of this protective cell type. Consistent with this, clin-
ical trials have suggested an increased risk of T1D in transplant
patients treated with anti-CD25 antibody (Baye´s et al., 2007;
Vendrame et al., 2010).
Another overlap was seen for a variant in ATXN2 that is highly
correlated with a missense variant within the SH2B3 gene
(R262W). The W262 nonancestral allele increases the levels of
T lymphocytes and the helper CD4+ T cell subset with similar
effect sizes, and it is positively associated with many auto-
immune diseases (such as type 1 diabetes and celiac disease),
as well as with hypertension and related pathologies (i.e.,
coronary heart disease and chronic kidney disease). Addition-
ally, this variant has been associated with several endo-
phenotypes in the general population, including platelet and
eosinophil levels as well as systolic and diastolic blood pressure
(http://www.genome.gov/gwastudies/). SH2B3 encodes the
adaptor protein LNK, whose mouse ortholog was earlier shown
to be a negative regulator of hematopoiesis, cytokine signaling,Cell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc. 247
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.and inflammation (Devallie`re and Charreau, 2011). An increase of
total T cells (CD3+ lymphocytes) and particularly of CD4+ T cells
resulting from the W262 allele may thereby result in loss of func-
tion. Furthermore, this observation is consistent with findings in
mouse models and humans suggesting the potential efficacy
of monoclonal antibodies against CD3 in T1D and other autoim-
mune diseases (Chatenoud, 2010).
Relevant to its function, the SH2B3-associated variant marks
an extended haplotype spanning 200 kb (Data S1, panel
22A), indicative of strong positive selection (Barreiro and
Quintana-Murci, 2010). During human evolution, a lymphocy-
tosis-associated variant may have been useful for thousands
of years in resistance to pathogens but, in recent less septic
environments, becomes a risk factor for autoimmunity.
Other genetic variants might also be enriched by balancing
selection to maintain a high degree of variation in immune cell
levels in a given population, increasing the chances for survival
of groups of individuals under different and often opposite envi-
ronmental pressures. Among our associated variants, clear evi-
dence of balancing selection was found in the HLA region
(Extended Experimental Procedures), consistent with its key
role in host defense and disease susceptibility.
In addition to coincident associations clearly satisfying strin-
gent criteria, other overlapping signals for variants affecting
both levels of specific cells and disease risk are likely genuine.
For example, the allele associated with a higher level of HLA-
DR+ (activated) T lymphocytes at CIITA is in moderate LD (r2 =
0.44) with the risk allele for Celiac disease (CD) (Trynka et al.,
2011). In this case, the lack of full coincidence at the same
SNP or a suitable proxy may be attributable to differences in
map resolution in different studies (the coverage at this locus
was low in the CD study). Furthermore, our top variant is in strong
LD (r2 = 0.99) with a variant showing suggestive association with
ulcerative colitis (McGovern et al., 2010).
Overall, the coincident associations between diseases and
immune traits have special potential to reveal sites for therapeutic
intervention, and indeed some of those detected had already
been selected as targets for pharmaceutical therapy (Table
S6C). It is also noteworthy that our work does not support
some previous claims—largely based on functional evidence—
about the involvement of specific cell type levels in specific dis-
eases. For instance, a protective role of CD39+-activated CD4+
Tregs in various autoimmune diseases has been suggested
(Chalmin et al., 2012; Fletcher et al., 2009), but no overlapping
association was observed between disease and the major ge-
netic variants affecting thequantitative regulation of this cell type.
Conclusions and Prospects
As part of the dynamic mounting and control of immune reac-
tions, our results reveal that DNA variation superimposes
powerful programmed regulation on various subtypes of leuko-
cytes. Interestingly, those showing the greatest estimated
inherited control are implicated in themore sophisticated cellular
functions, such as regulatory T cells, which were phylogeneti-
cally the last to evolve and are also the last to appear in
ontogenesis.
A number of the genetic associations identified here explain an
appreciable fraction of trait heritability and demonstrate theCell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc. 249
Figure 5. Proportion of Heritability Explained
The bar plots show the heritability of each trait (represented by a bar) for which genetic association was detected. The proportion of heritability explained by the
detected loci is indicated in dark blue, and the proportion of heritability that remains to be explained is shown in light blue. Bars are grouped in their corresponding
biological category, as specified in Table S1B. See also Tables S2A and S5.feasibility of genetic dissection of quantitative variation of spe-
cific immune cell types. At least three factors likely contribute
to the unusually high degree of explained heritability, which
contrasts sharply with typical observations in GWAS for quanti-
tative traits, for which ‘‘missing heritability’’ is the norm. First,
examiningmore restricted cell types avoids dilution and possible
opposing effects in mixtures of leukocytes; this notion is consis-
tent, for example, with findings of large effect size variants asso-
ciated with fetal hemoglobin that have no detectable effects on
total hemoglobin (Uda et al., 2008). Second, the large genetic
effect sizes could be related to intrinsic properties of the immune
response, which, confronted at the population level with an
unpredictable and changing environment, must ensure optimal
primed variability in the quantitative levels of immune cell types.
Finally, the sequencing-based approach employed provides250 Cell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc.assessment of genomic variation at an unprecedented level of
resolution, except for very rare SNPs and indels.
The 13 reported loci point to specific DNA polymorphisms
and putative proteins and mechanisms involved in regulation
of cellular immunity. They also identify specific molecules
and cell subtypes involved in a range of diseases, particularly
autoimmune diseases, reflecting the dramatically shifting
evolutionary balance between the optimization of effective
response to pathogens and the risk of autoimmunity. Given
that several association signals may have not been captured
in this study due to sample size restrictions—and in most pre-
vious disease GWAS due to their restriction to common ubiq-
uitous variants—many more overlapping associations are likely
to be forthcoming when the approach described here is
extended to larger samples. These overlaps should include
multiple associations for the same trait and disease, reinforc-
ing evidence of causal relationships between them. Our survey
also reveals primary candidate genes to be resequenced in
searches for both germline mutations in patients with selective
and combined immunodeficiencies and driver somatic muta-
tions in patients with circulating hematopoietic malignancies.
Some of the observations presented here also hint at previ-
ously undocumented involvement of the immune system in
maladies such as Parkinson’s disease, though rigorous testing
in appropriate cohorts is required to assess these possibilities
further.
For some autoimmune pathologies, the mechanistic clues
involving specific cell types suggest targets but also concomi-
tant risks for therapeutic interventions, with some drugs already
in use or under clinical experimentation targeting the associated
protein products for a number of loci. Further functional studies
to explicate the effects of the variants on identified cell types
could foster therapies aimed at controlling the numbers of those
cell types to help regulate the immune system safely, preventing
occurrence or lessening severity of autoimmune diseases.EXPERIMENTAL PROCEDURES
Study Population
The SardiNIA project is a longitudinal study that recruited and phenotyped
6,148 individuals, males and females, aged 14–102, from a cluster of four
towns in the Lanusei Valley (Pilia et al., 2006), located on the central east coast
of Sardinia, Italy. During clinic visits, fresh blood samples were collected and
used for both DNA extraction and flow cytometric measurements. Initially,
1,629 individuals were characterized for the immune-related phenotypes
described below, followed by an additional 1,241 individuals from the same
cohort, to extend the sample size and validate the identified association re-
sults. Ethical permission for this study was granted by the Regional Ethics
Committee (No 2009/0016600).
Flow Cytometric Measurements
Immunophenotyping was carried out by flow cytometry on fresh blood
samples, and cell phenotyping was performed within 2 hr after collection to
avoid any time-dependent artifacts. We selected and tested a set of multi-
plexed fluorescent antibodies to characterize the major leukocyte cell popula-
tions in peripheral blood, including monocytes, granulocytes, circulating
dendritic cells, and lymphocytes subdivided into NK, B, and T cells and their
subsets (Extended Experimental Procedures, Figure S1, and Table S1A). In
particular, we assessed regulatory T cells (CD25hi, CD127-), subdivided into
resting, activated, and cytokine-secreting nonsuppressive cells (Miyara
et al., 2009; Shevach, 2000). We also used the HLA-DR marker to assess
the activation status of T and NK cells and both the chemokine receptor
CCR7 and the phosphatase CD45RA antigens to distinguish between naive,
central memory (CM), effector memory (EM), and terminally differentiated
(TD) T cell subsets (Sallusto et al., 1999). Moreover, in selected T cell subpop-
ulations, we assessed the positivity for the ectoenzyme CD39 and the CD28
costimulatory antigen (Keir and Sharpe, 2005). Finally, cDCs were separated
into myeloid (mDCs) and plasmacytoid (pDCs) cells and were further subdi-
vided by the expression of the adhesion molecule CD62L and the costimula-
tory ligand CD86 (Steinman and Banchereau, 2007; Ohnmacht et al., 2009).
For all cell populations, wemeasured both absolute counts (AC) and the pro-
portion of each typewith respect to their progenitor cell lineages, expressed as
percentages of the levels of parent (%P) and grandparent (%GP) cell lineages
(Figure 1 and Table S1B). For example, helper CD4+ T cells were evaluated
relative to CD3+ cells (parent cell population representing all T cells) and to to-
tal lymphocytes (grandparent cell population). Percentages with respect to
parental and grandparental cell populations lead to more robust measures
of cell levels by reducing variability in measurements resulting from samplehandling or fluctuations by transient environmental factors that affect the total
leukocyte counts. These percentages may also reveal association with molec-
ular changes that alter factors involved in feedback mechanisms responsible
for maintaining a balance between cells. Finally, we assessed the specific ra-
tios of cell types that are widely clinically used and that examine the balance
between T and B cells and between helper (CD4) and cytotoxic (CD8) T cells.
Overall, we examined 95 absolute counts, 94 percentages with respect to
parent cells, 80 percentages with respect to grandparent cells, and 3 ratios
between cell subsets (Table S1B).
To ensure reproducible measures over time, we followed a rigorous stan-
dardization protocol (Extended Experimental Procedures). In brief, (1) we daily
adjusted internal parameters of FACS using standardized fluorescent beads to
check and correct for laser wear and fluidic instability, and (2) we weekly vali-
dated cell counts through suitable quality control of stabilized blood samples.
To directly assess reproducibility, we repeated the FACS measurements in 35
participants sampled at least 3 months after their initial enrollment, finding
overall high reproducibility (median value for all traits 0.90, mean 0.85, stan-
dard deviation 0.13) (Table S2B).
Heritability Estimation and Bivariate Analysis
We estimated heritability for all inverse-normalized traits in the first 1,629 im-
munophenotyped individuals (comprising 211 unrelated individuals and 1,418
subjects grouped in 249 families, leading to 567 sib pairs, 30 half-sib pairs,
248 cousins pairs, 609 parent-child pairs, 32 grandparent-grandchild pairs,
and 561 avuncular pairs for analysis), including age and gender as covariates.
Furthermore, familial clustering of blood sampling (i.e., same-day sampling of
closely related individuals), which could bias heritability estimates, was
checked for and excluded (Extended Experimental Procedures).
We also performed a bivariate analysis to estimate the phenotypic and
genetic correlations between traits. In particular, for each trait pair, the
phenotypic correlation was computed as the Spearman coefficient, whereas
the genetic correlation was estimated as the cross trait-cross individual
additive genetic covariance between traits normalized by the geometric
mean of the individual trait genetic variances and by the kinship coefficient
of pairs of individuals. We then used a hierarchical clustering analysis that
successively connected the most similar traits, based on the estimated
phenotypic and genetic correlation coefficients (Extended Experimental
Procedures).
Genotyping and Whole-Genome Sequencing
The entire SardiNIA cohort was characterized using two Illumina custom
arrays: the Cardio-MetaboChip and the ImmunoChip. These arrays were
designed by international consortia to genotype regions of prior interest in
metabolic and immune-related traits and diseases, respectively (Cortes and
Brown, 2011; Voight et al., 2012), and resulted in quality-controlled 284,722
SNPs derived from both arrays. We also whole-genome sequenced 1,146
Sardinians at low pass (average 4-fold coverage) (Extended Experimental
Procedures).
Statistical and Bioinformatical Analyses
We performed a GWAS for each trait, analyzing 8.2 million variants
assembled from the integration of the two assessed arrays and markers
imputed with the Sardinian sequencing reference panel (Table S3 and
Extended Experimental Procedures) (Li et al., 2009). Association was eval-
uated by a variance component-based regression analysis to account for
family structure, using the same covariates as in heritability estimation
(Chen and Abecasis, 2007). Traits were normalized using inverse normal
transformation.
We selected all independently associated variants for each trait (r2 < 0.1 or
those remaining significant in a stepwise conditional analysis), using a sig-
nificance threshold of p < 5.26 3 1010. This threshold corresponds to the
standard genome-wide threshold of 5 3 108 after further adjustment for 95
independent tests (the number of absolute cell count measurements).
Although this approach is conservative given the high interdependency of
cell lineages, it ensures the robustness of our findings. We successively
removed poorly imputed variants and then eliminated redundant trait-variant
associations by prioritizing the most strongly associated variants at eachCell 155, 242–256, September 26, 2013 ª2013 Elsevier Inc. 251
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locus and removing those in LD.We also included two suggestive associations
(5.26 3 1010 < p < 5 3 108) at the previously described SH2B3/ATXN2 and
SLFN13 gene regions (Ferreira et al., 2010).
To validate findings, we measured the corresponding associated immuno-
phenotypes in an additional 1,241 individuals from the same SardiNIA cohort
and genotyped variants representing novel signals that were not supported
by a directly genotyped variant (r2 > 0.85). Variants showing an excess of
discordant genotypes or less significant p values after addition of the extended
sample were excluded from further analyses (Tables S4A and S4B and
Extended Experimental Procedures).
To calculate the amount of phenotypic variance explained by genetic fac-
tors, for each trait, we fitted a linear model containing age, gender, and all of
the independent SNPs associated with that specific trait (full model) and a
linear model containing only age and gender (basic model). The variance
explained was calculated as the difference of the r2-adjusted quantity
observed in the full and basic models (Table S2A).
To prioritize candidate gene(s) at each locus, we searched for correlated
expression quantitative trait loci (eQTLs), coding variants, and nearby
genes involved in immune-related disorders, as reported inOMIM (OnlineMen-
delian Inheritance in Man) or implicated in immunity in previous studies (Tables
S4C andS4D). Bioinformatic analyseswere carried out to characterize variants
and genes, including colocalization with regulatory features and their potential
for pharmaceutical interest (Tables S6A, S6B, and S6C). Lastly, to assess
possible impact of the detected variants on disease susceptibility, we
searched for coincident associations in public repositories (Table 2), such as
the GWAS catalog (http://www.genome.gov/gwastudies/) and ImmunoBase
(http://www.immunobase.org/) (Extended Experimental Procedures).
A schematic overview of the overall study design is depicted in Figure S4.
The Extended Experimental Procedures provide details about the study
design, genetic and immunophenotypic data collection, and statistical and
bioinformatic analyses.
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